Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia

Intensive Care Med. 1994;20(3):193-8. doi: 10.1007/BF01704699.

Abstract

Objective: to investigate the epidemiology of infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia (VAP).

Design: prospective clinical study.

Setting: a medical-surgical ICU in a university hospital.

Patients: we followed-up 568 mechanically ventilated patients and 83 episodes of VAP with etiologic diagnosis in 72 patients were retained for analysis.

Results: Ps. aeruginosa was isolated in 22 (26.5%) episodes in 18 patients. Of these episodes 7 were directly responsible for death. Using logistic regression analysis, the risk of VAP due to Ps. aeruginosa was increased in patients with chronic obstructive pulmonary disease (relative risk (RR) = 29.9, 95% confidence interval (CI) = 4.86-184.53), a mechanical ventilation period longer than 8 days (RR = 8.1, 95% CI = 1.01-65.40) and prior use of antibiotics (RR = 5.5, 95% CI = 0.88-35.01).

Conclusions: patients with VAP and these factors have a greater risk of infection by Ps. aeruginosa and empirical therapy for these episodes should include anti-pseudomonal activity until etiologic diagnosis is established.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Cause of Death
  • Confidence Intervals
  • Cross Infection / diagnosis
  • Cross Infection / epidemiology
  • Cross Infection / etiology*
  • Cross Infection / therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Infection Control*
  • Intensive Care Units
  • Length of Stay
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pneumonia / diagnosis
  • Pneumonia / epidemiology
  • Pneumonia / etiology*
  • Pneumonia / therapy
  • Prospective Studies
  • Pseudomonas Infections / diagnosis
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / etiology*
  • Pseudomonas Infections / therapy
  • Pseudomonas aeruginosa*
  • Respiration, Artificial / adverse effects*
  • Risk Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents